PRDX1 knockdown promotes erastin-induced ferroptosis and impedes diffuse large B-cell lymphoma development by inhibiting the MAPK/ERK pathway

  • 0Department of Hematology, First Affiliated Hospital of Gannan Medical University, No. 128, Jinling Road, Economic Development District, Ganzhou City, Jiangxi Province, 341000, China.

|

|

Summary

This summary is machine-generated.

Knocking down peroxiredoxin 1 (PRDX1) enhances ferroptosis in diffuse large B-cell lymphoma (DLBCL) cells by inhibiting the MAPK/ERK pathway. This finding suggests PRDX1 as a potential therapeutic target for DLBCL treatment.

Area Of Science

  • Oncology
  • Cell Biology
  • Molecular Mechanisms

Background

  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematological malignancy.
  • DLBCL cells exhibit sensitivity to ferroptosis, a regulated form of cell death.
  • Peroxiredoxin 1 (PRDX1) is implicated in cellular processes relevant to cancer progression.

Purpose Of The Study

  • To investigate the role of PRDX1 in ferroptosis within DLBCL.
  • To elucidate the molecular mechanisms by which PRDX1 influences ferroptosis and DLBCL progression.

Main Methods

  • PRDX1 expression analysis in DLBCL tissues and cells via bioinformatics and qPCR.
  • In vitro assessment of PRDX1's impact on DLBCL cell proliferation, apoptosis, migration, invasion, and ferroptosis.
  • In vivo validation using a xenograft tumor model.
  • Transcriptome sequencing to identify PRDX1-mediated pathways and MAPK/ERK pathway modulation using anisomycin.

Main Results

  • PRDX1 expression is upregulated in DLBCL.
  • PRDX1 knockdown inhibits DLBCL cell proliferation, migration, invasion, and tumor growth, while promoting apoptosis.
  • PRDX1 knockdown enhances erastin-induced ferroptosis, indicated by increased iron and MDA, and decreased GSH, COX2, GPX4, and SLC7A11 protein levels.
  • PRDX1 knockdown reduces MAPK/ERK pathway phosphorylation, an effect reversed by anisomycin.

Conclusions

  • PRDX1 knockdown promotes ferroptosis and hinders DLBCL progression by inhibiting the MAPK/ERK pathway.
  • Targeting PRDX1 represents a potential therapeutic strategy for DLBCL.